EXL (EXLS) Tops Q4 EPS by 6c; Offers 2022 Guidance

EXL (NASDAQ: EXLS) reported Q4 EPS of $1.21, $0.06 better than the analyst estimate of $1.15. Revenue for the quarter came in at $295.5 million versus the consensus estimate of $290.5 million.

GUIDANCE:

EXL sees FY2022 EPS of $5.35-$5.60, versus the consensus of $4.98. EXL sees FY2022 revenue of $1.28-1.31 billion, versus the consensus of $1.25 billion.

For earnings history and earnings-related data on EXL (EXLS) click here.

You May Also Be Interested In

• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
• Aebi Schmidt Holding AG (AEBI) Reports Q2 results; offers guidance
• Cellectar Biosciences (CLRB) Misses Q2 EPS by 9c